Transgenomic to Hold Second Quarter Financial Results Conference Call on August 1, 2012

Transgenomic to Hold Second Quarter Financial Results Conference Call on August 1, 2012

today announced the following Webcast:

To access the call via telephone, call 800-862-9098 from the U.S. or Canada or 785-424-1051 for international participants and enter conference ID TRANS. A telephone replay will be available from 6:00 p.m. Eastern Time on August 1, 2012 through 11:59 p.m. Eastern Time on August 15, 2012 by dialing 800-753-5212 (domestic) or 402-220-2673 (international).

Transgenomic, Inc. () is a global biotechnology company advancing personalized medicine in cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. The company has three complementary business divisions: Transgenomic Pharmacogenomic Services is a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development; Transgenomic Clinical Laboratories which specializes in molecular diagnostics for cardiology, neurology, mitochondrial disorders, and oncology; and Transgenomic Diagnostic Tools which produces equipment, reagents, and other consumables that empower clinical and research applications in molecular testing and cytogenetics. Transgenomic believes there is significant opportunity for continued growth across all three businesses by leveraging their synergistic capabilities, technologies, and expertise. The company actively develops and acquires new technology and other intellectual property that strengthens its leadership in personalized medicine.

Suggested Articles

Wedding Five Prime Therapeutics’ cabiralizumab to Bristol-Myers Squibb’s checkpoint inhibitor Opdivo has proved to be a bust in pancreatic cancer.

Sean Harper and Beth Seidenberg tell FierceBiotech how and why they set up their own VC firm, Westlake Village BioPartners.

Imara is looking to cap a good 2019 with an initial public offering in 2020. The rare disease biotech wants $86 million on the Nasdaq.